PortalPublikationenDalbavancin as Primary and Sequential Treatment for Gram-Pos...

Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna

Standard

Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna. / Tobudic, Selma; Forstner, Christina; Burgmann, Heinz; Lagler, Heimo; Ramharter, Michael; Steininger, Christoph; Vossen, Matthias G; Winkler, Stefan; Thalhammer, Florian.

in: CLIN INFECT DIS, Jahrgang 67, Nr. 5, 16.08.2018, S. 795-798.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tobudic, S, Forstner, C, Burgmann, H, Lagler, H, Ramharter, M, Steininger, C, Vossen, MG, Winkler, S & Thalhammer, F 2018, 'Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna', CLIN INFECT DIS, Jg. 67, Nr. 5, S. 795-798. https://doi.org/10.1093/cid/ciy279

APA

Tobudic, S., Forstner, C., Burgmann, H., Lagler, H., Ramharter, M., Steininger, C., Vossen, M. G., Winkler, S., & Thalhammer, F. (2018). Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna. CLIN INFECT DIS, 67(5), 795-798. https://doi.org/10.1093/cid/ciy279

Vancouver

Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C et al. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna. CLIN INFECT DIS. 2018 Aug 16;67(5):795-798. https://doi.org/10.1093/cid/ciy279

Bibtex

@article{db6cba7518c04e748fcc4f9c09dad14b,
title = "Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna",
abstract = "The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.",
keywords = "Journal Article",
author = "Selma Tobudic and Christina Forstner and Heinz Burgmann and Heimo Lagler and Michael Ramharter and Christoph Steininger and Vossen, {Matthias G} and Stefan Winkler and Florian Thalhammer",
year = "2018",
month = aug,
day = "16",
doi = "10.1093/cid/ciy279",
language = "English",
volume = "67",
pages = "795--798",
journal = "CLIN INFECT DIS",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna

AU - Tobudic, Selma

AU - Forstner, Christina

AU - Burgmann, Heinz

AU - Lagler, Heimo

AU - Ramharter, Michael

AU - Steininger, Christoph

AU - Vossen, Matthias G

AU - Winkler, Stefan

AU - Thalhammer, Florian

PY - 2018/8/16

Y1 - 2018/8/16

N2 - The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.

AB - The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.

KW - Journal Article

U2 - 10.1093/cid/ciy279

DO - 10.1093/cid/ciy279

M3 - SCORING: Journal article

C2 - 29659732

VL - 67

SP - 795

EP - 798

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 5

ER -